OmniAb, Inc. (NASDAQ:OABIW – Get Free Report) saw a significant growth in short interest in August. As of August 14th, there was short interest totaling 18,488 shares, a growth of 98.0% from the July 30th total of 9,338 shares. Based on an average daily volume of 6,868 shares, the short-interest ratio is currently 2.7 days.
OmniAb Stock Performance
Shares of OABIW stock traded up $0.01 during trading on Monday, hitting $0.26. The company’s stock had a trading volume of 3,172 shares, compared to its average volume of 16,489. The business has a fifty day moving average of $0.11 and a 200-day moving average of $0.10. OmniAb has a 52 week low of $0.04 and a 52 week high of $0.40.
OmniAb Company Profile
OmniAb, Inc is a clinical‐stage biotechnology company specializing in the discovery and optimization of therapeutic antibodies. The company leverages a broad suite of proprietary platform technologies designed to accelerate antibody generation, characterization, and engineering. By integrating advanced immunization methods with high‐throughput screening and bioinformatics, OmniAb aims to streamline the development of next‐generation biologics across a range of disease areas.
At the core of OmniAb’s offering are its transgenic animal platforms, which have been engineered to produce fully human antibodies, and its complementary in vitro display and single‐cell screening capabilities.
See Also
- Five stocks we like better than OmniAb
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Receive News & Ratings for OmniAb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OmniAb and related companies with MarketBeat.com's FREE daily email newsletter.
